| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sukhtej Sahni, B S Chavan, Ajeet Sidana, Priyanka Kalra, Gurjit Kau. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. The Indian journal of medical research. vol 144. issue 5. 2017-07-21. PMID:28361822. |
comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: a pilot study. |
2017-07-21 |
2023-08-13 |
Not clear |
| Sukhtej Sahni, B S Chavan, Ajeet Sidana, Priyanka Kalra, Gurjit Kau. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. The Indian journal of medical research. vol 144. issue 5. 2017-07-21. PMID:28361822. |
clozapine may be more useful in treatment-naive patients with first-episode schizophrenia for better symptoms control and improving quality of life. |
2017-07-21 |
2023-08-13 |
Not clear |
| Sukhtej Sahni, B S Chavan, Ajeet Sidana, Priyanka Kalra, Gurjit Kau. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. The Indian journal of medical research. vol 144. issue 5. 2017-07-21. PMID:28361822. |
the current study was carried out to compare the efficacy and tolerability of clozapine versus risperidone in treatment-naive, first-episode patients of schizophrenia. |
2017-07-21 |
2023-08-13 |
Not clear |
| Sarah Barber, Uwaila Olotu, Martina Corsi, Andrea Ciprian. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. The Cochrane database of systematic reviews. vol 3. 2017-07-20. PMID:28333365. |
clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. |
2017-07-20 |
2023-08-13 |
Not clear |
| Sarah Barber, Uwaila Olotu, Martina Corsi, Andrea Ciprian. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. The Cochrane database of systematic reviews. vol 3. 2017-07-20. PMID:28333365. |
between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. |
2017-07-20 |
2023-08-13 |
Not clear |
| Wei Zheng, Xiao-Lan Cao, Gabor S Ungvari, Ying-Qiang Xiang, Tong Guo, Zheng-Rong Liu, Yuan-Yuan Wang, Brent P Forester, Stephen J Seiner, Yu-Tao Xian. Electroconvulsive Therapy Added to Non-Clozapine Antipsychotic Medication for Treatment Resistant Schizophrenia: Meta-Analysis of Randomized Controlled Trials. PloS one. vol 11. issue 6. 2017-07-10. PMID:27285996. |
this meta-analysis of randomized controlled trials (rcts) examined the efficacy and safety of the combination of electroconvulsive therapy (ect) and antipsychotic medication (except for clozapine) versus the same antipsychotic monotherapy for treatment-resistant schizophrenia (trs). |
2017-07-10 |
2023-08-13 |
Not clear |
| Wei Zheng, Yu-Tao Xiang, Xin-Hu Yang, Ying-Qiang Xiang, Jose de Leo. Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials. The Journal of clinical psychiatry. vol 78. issue 5. 2017-06-16. PMID:28355041. |
clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. |
2017-06-16 |
2023-08-13 |
Not clear |
| Wei Zheng, Yu-Tao Xiang, Xin-Hu Yang, Ying-Qiang Xiang, Jose de Leo. Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials. The Journal of clinical psychiatry. vol 78. issue 5. 2017-06-16. PMID:28355041. |
to meta-analyze randomized controlled trials (rcts) for the efficacy and safety of adjunctive antiepileptic drugs (aeds) to augment clozapine therapy for treatment-resistant schizophrenia. |
2017-06-16 |
2023-08-13 |
Not clear |
| Susan L Rossell, Paul S Francis, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia Dean, Dennis Liu, Denny Meyer, Erica Neill, Andrea Phillipou, Jerome Sarris, David J Castl. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. BMC psychiatry. vol 16. issue 1. 2017-06-15. PMID:27629871. |
n-acetylcysteine (nac) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. |
2017-06-15 |
2023-08-13 |
Not clear |
| Susan L Rossell, Paul S Francis, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia Dean, Dennis Liu, Denny Meyer, Erica Neill, Andrea Phillipou, Jerome Sarris, David J Castl. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. BMC psychiatry. vol 16. issue 1. 2017-06-15. PMID:27629871. |
clozapine is an effective treatment for a proportion of people with schizophrenia (sz) who are resistant to the beneficial effects of other antipsychotic drugs. |
2017-06-15 |
2023-08-13 |
Not clear |
| Erlend Bugge, Trygve Nissen, Rolf Wyn. Probable clozapine-induced parenchymal lung disease and perimyocarditis: a case report. BMC psychiatry. vol 16. issue 1. 2017-06-09. PMID:27931201. |
clozapine is the archetypical atypical antipsychotic, its primary indication being treatment resistant schizophrenia. |
2017-06-09 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Jimmy Lee, Gagan Fervaha, George Foussias, Ofer Agid, Gary Remingto. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial. The Journal of clinical psychiatry. vol 78. issue 2. 2017-06-08. PMID:28234436. |
to examine effects of different antipsychotic discontinuation strategies on clinical outcomes in patients with schizophrenia undergoing a switch to clozapine. |
2017-06-08 |
2023-08-13 |
Not clear |
| Nina R Schooler, Stephen R Marder, K N R Chengappa, Georgios Petrides, Donna Ames, William C Wirshing, Marjorie McMeniman, Robert W Baker, Haranath Parepally, Daniel Umbricht, John M Kan. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. The Journal of clinical psychiatry. vol 77. issue 5. 2017-06-07. PMID:27035871. |
clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. |
2017-06-07 |
2023-08-13 |
Not clear |
| Nina R Schooler, Stephen R Marder, K N R Chengappa, Georgios Petrides, Donna Ames, William C Wirshing, Marjorie McMeniman, Robert W Baker, Haranath Parepally, Daniel Umbricht, John M Kan. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. The Journal of clinical psychiatry. vol 77. issue 5. 2017-06-07. PMID:27035871. |
clozapine remains the only medication indicated for refractory schizophrenia. |
2017-06-07 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Magnús Haraldsson, Halldóra Jónsdóttir, Engilbert Sigurdsso. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC psychiatry. vol 16. issue 1. 2017-06-05. PMID:27955666. |
neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in iceland. |
2017-06-05 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Magnús Haraldsson, Halldóra Jónsdóttir, Engilbert Sigurdsso. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC psychiatry. vol 16. issue 1. 2017-06-05. PMID:27955666. |
however, in iceland where clozapine monitoring is less stringent allows an observational study to be done on the risk of agranulocytosis and neutropenia during treatment with clozapine compared with other antipsychotics among patients with schizophrenia. |
2017-06-05 |
2023-08-13 |
Not clear |
| Chittaranjan Andrad. Antipsychotic Drugs in Schizophrenia: Relative Effects in Patients With and Without Treatment Resistance. The Journal of clinical psychiatry. vol 77. issue 12. 2017-06-05. PMID:28086018. |
at the risk of oversimplification, it appears that clozapine retains its preeminence in medication-refractory schizophrenia and that clozapine and olanzapine are both associated with superior efficacy outcomes in non-refractory patients. |
2017-06-05 |
2023-08-13 |
human |
| S Schreiter, A Hasan, T Majic, A Wullschleger, M Schouler-Ocak, F Bermpohl, S Gutwinsk. [Obsessive-Compulsive Symptoms in a Sample of Patients with Chronic Schizophrenia Under Clozapine Treatment]. Fortschritte der Neurologie-Psychiatrie. vol 84. issue 11. 2017-05-30. PMID:27846652. |
[obsessive-compulsive symptoms in a sample of patients with chronic schizophrenia under clozapine treatment]. |
2017-05-30 |
2023-08-13 |
Not clear |
| Maurizio Pompili, Ross J Baldessarini, Alberto Forte, Denise Erbuto, Gianluca Serafini, Andrea Fiorillo, Mario Amore, Paolo Girard. Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview. International journal of molecular sciences. vol 17. issue 10. 2017-05-12. PMID:27727180. |
clozapine remains the only treatment with an fda-recognized indication for reducing suicidal risk (in schizophrenia). |
2017-05-12 |
2023-08-13 |
Not clear |
| Helio Elkis, Peter F Buckle. Treatment-Resistant Schizophrenia. The Psychiatric clinics of North America. vol 39. issue 2. 2017-05-01. PMID:27216902. |
although treatment-resistant schizophrenia (trs) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy. |
2017-05-01 |
2023-08-13 |
Not clear |